HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Analgesia
Conditions
Analgesia
Trial Timeline
Jun 5, 2019 → Jan 7, 2021
NCT ID
NCT03974932About HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011
HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011 is a phase 3 stage product being developed by Heron Therapeutics for Analgesia. The current trial status is completed. This product is registered under clinical trial identifier NCT03974932. Target conditions include Analgesia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03974932 | Phase 3 | Completed |
Competing Products
20 competing products in Analgesia
Other Products from Heron Therapeutics
SUSTOLApproved
77
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenApproved
77
Bupivacaine HClApproved
77
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenApproved
77
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionApproved
77